Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

PURPOSE: Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bekaii-Saab, Tanios, Phelps, Mitch A., Li, Xiaobai, Saji, Motoyasu, Goff, Laura, Kauh, John Sae Wook, O'Neil, Bert H., Balsom, Stephanie, Balint, Catherine, Liersemann, Ryan, Vasko, Vasily V., Bloomston, Mark, Marsh, William, Doyle, L. Austin, Ellison, Gilian, Grever, Michael, Ringel, Matthew D., Villalona-Calero, Miguel A.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2011
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107751/
https://ncbi.nlm.nih.gov/pubmed/21519026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.9473
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares